Jane Street’s Fulcrum Therapeutics FULC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$123K Buy
33,200
+9,200
+38% +$34.5K ﹤0.01% 10452
2026
Q2
$87.8K Buy
24,000
+2,700
+13% +$16.4K ﹤0.01% 10667
2026
Q1
$163K Sell
21,300
-15,400
-42% -$143K ﹤0.01% 10319
2025
Q4
$415K Buy
+36,700
New +$373K ﹤0.01% 8117
2024
Q4
– Sell
-70,200
Closed -$251K – 9815
2024
Q3
$251K Buy
+70,200
New +$521K ﹤0.01% 8317
2022
Q1
– Sell
-13,400
Closed -$237K – 10530
2021
Q4
$237K Sell
13,400
-26,900
-67% -$533K ﹤0.01% 8562
2021
Q3
$1.14M Buy
+40,300
New +$764K ﹤0.01% 5654

Other funds holding FULC

Jane Street's FULC Position: Q3 2026 in Review

Jane Street reduced its Fulcrum Therapeutics (FULC) stake by 76% in Q3 2026, selling an estimated $6.36M and leaving 522,521 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #5224.

Jane Street first reported a position in FULC in Q3 2021 and has held it in 20 quarters since. The position peaked at $8.12M in Q2 2026. 151 funds tracked by Wall St. Rank hold FULC as of Q3 2026.

  • Jane Street held 522,521 shares of Fulcrum Therapeutics worth $1.93M as of Q3 2026.
  • Jane Street sold 1,694,977 Fulcrum Therapeutics shares in Q3 2026, an estimated $6.36M.
  • Fulcrum Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q3 2026, its #5224 holding.
  • Jane Street first reported a position in Fulcrum Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Jane Street's Fulcrum Therapeutics position peaked at $8.12M in Q2 2026.
  • 151 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2026.

Based on Jane Street's 13F filing for Q3 2026, filed 12 Nov 2026.